Primary Biliary Cholangitis in Medicare Population: The Impact on Mortality and Resource Use

Mehmet Sayiner, Pegah Golabi, Maria Stepanova, Issah Younossi, Fatema Nader, Andrei Racila, Zobair M. Younossi – 17 July 2018 – Primary biliary cholangitis (PBC) is a disease of small bile ducts, which can lead to morbidity and mortality. Our aim was to assess recent trends in mortality and healthcare use of PBC patients in the Medicare program. Data from Medicare beneficiaries between 2005 and 2015 (5% random samples) were used. The diagnosis of PBC was established with International Classification of Diseases‐9 code 571.6 used for both primary and secondary diagnoses.

Liver‐Selective MMP‐9 Inhibition in the Rat Eliminates Ischemia‐Reperfusion Injury and Accelerates Liver Regeneration

Xiangdong Wang, Ana C. Maretti‐Mira, Lei Wang, Laurie D. DeLeve – 17 July 2018 – Recruitment of liver sinusoidal endothelial cell progenitor cells (sprocs) from the bone marrow by vascular endothelial growth factor‐stromal cell‐derived factor‐1 (VEGF‐sdf‐1) signaling promotes recovery from injury and drives liver regeneration. Matrix metalloproteinases (MMPs) can proteolytically cleave VEGF, which might inhibit progenitor cell recruitment, but systemic matrix metalloproteinase inhibition might prevent efflux of progenitors from the bone marrow.

Serum Alanine Aminotransferase Elevations in Survivors of Childhood Cancer: A Report From the St. Jude Lifetime Cohort Study

Daniel M. Green, Mingjuan Wang, Matthew J. Krasin, DeoKumar Srivastava, Mary V. Relling, Carrie R. Howell, Kirsten K. Ness, Sue C. Kaste, William Greene, Dennis W. Jay, Israel Fernandez‐Pineda, Ching‐Hon Pui, Sima Jeha, Michael W. Bishop, Wayne L. Furman, Leslie L. Robison, Melissa M. Hudson – 17 July 2018 – The purpose of this study was to define the prevalence of and risk factors for elevated serum alanine aminotransferase (ALT) level among adult childhood cancer survivors (CCS). The study cohort comprised 2,751 CCS from the St.

Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct‐Acting‐Antiviral Period?

Mamta K. Jain, Mae Thamer, George Therapondos, Mitchell L. Shiffman, Onkar Kshirsagar, Christopher Clark, Robert J. Wong – 17 July 2018 – Direct‐acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment is unknown. The objective of this study was to examine the extent and predictors of HCV treatment in the pre‐DAA and post‐DAA periods in four large, diverse health care settings in the United States.

Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension—The Devil Is in the Details

Raj Vuppalanchi, Karan Mathur, Maximillian Pyko, Niharika Samala, Naga Chalasani – 17 July 2018 – Noncirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as prehepatic, hepatic (presinusoidal and sinusoidal) and posthepatic. Some common etiologies of NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular regenerative hyperplasia (hepatic).

Liver Stiffness Measurements in Patients with Noncirrhotic Portal Hypertension—The Devil Is in the Details

Raj Vuppalanchi, Karan Mathur, Maximillian Pyko, Niharika Samala, Naga Chalasani – 17 July 2018 – Noncirrhotic portal hypertension (NCPH) is often a diagnostic challenge due to signs and symptoms of portal hypertension that overlap with cirrhosis. The etiology of NCPH is broadly classified as prehepatic, hepatic (presinusoidal and sinusoidal) and posthepatic. Some common etiologies of NCPH encountered in clinical practice include portal vein thrombosis (prehepatic) and nodular regenerative hyperplasia (hepatic).

Nonheavy Drinking and Worsening of Noninvasive Fibrosis Markers in Nonalcoholic Fatty Liver Disease: A Cohort Study

Yoosoo Chang, Yong Kyun Cho, Yejin Kim, Eunju Sung, Jiin Ahn, Hyun‐Suk Jung, Kyung Eun Yun, Hocheol Shin, Seungho Ryu – 17 July 2018 – The effect of modest alcohol consumption on fibrosis progression in the general population with nonalcoholic fatty liver disease (NAFLD) remains unclear. We examined the association of nonheavy alcohol consumption with worsening of noninvasive fibrosis indices in a large‐scale, low‐risk population with NAFLD. A cohort study was performed in 58,927 Korean adults with NAFLD and low fibrosis scores who were followed for a median of 4.9 years.

Subscribe to